EDITAS MEDICINE, INC. Editas Medicine, Inc. announced the appointment of Baisong Mei, M.D., Ph.D., as the Company's Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company's pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology. Dr. Mei brings to Editas more than 20 years of experience in the biotech and pharmaceutical industry, spanning the entire drug development life cycle across multiple disease areas, including hematology, neurology, and other diseases.
During his career, Dr. Mei has demonstrated a strong track record in bringing novel medicines through clinical development and global regulatory approval, including Alprolix®, Eloctate®, and Onpattro®. He has led clinical development for multiple new molecular entities (protein, siRNA, gene therapy, and small molecule), from first in human to Phase 3 studies (including pediatric studies) and to regulatory approval in the U.S., EU, Japan, China, and other regions. Before working in clinical development, Dr. Mei had a successful career in drug discovery research and CMC development where his leadership and inventions led to the discoveries of one approved drug (Jivi®) and one drug candidate with recent BLA filing (efanesoctocog alfa).
Dr. Mei has also led several external strategic partnership collaborations for clinical development and drug discovery. Dr. Mei joins Editas Medicine from Sanofi, where he served as Senior Global Project Head in Rare Disease and Rare Blood Disorders. His leadership was critical to the clinical development pipeline in several rare diseases in hematology, neurology, and nephrology.
Prior to Sanofi, Dr. Mei was the Therapeutic Area Head for Hematology Clinical Development at Biogen. In this role, he led programs in non-malignant hematology, including hemophilia, sickle cell disease, and beta thalassemia clinical programs. Earlier in his career, Dr. Mei held leadership positions with increasing responsibilities in drug discovery research and CMC development at Biogen and Bayer. Dr. Mei earned his Ph.D. from The University of Toledo in Ohio and received his medical education at Bengbu Medical College and Wuhan University School of Medicine in China.
Dr. Mei also held postdoctoral fellowships at the University of California San Francisco and the University of California Berkeley. He was a faculty member at the Wuhan University School of Medicine in his early career.
